Loading...
NEJM Research Summary
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
New England Journal of Medicine
Mar 11
1 min read
New England Journal of Medicine
March 11
1 min read
New England Journal of Medicine
March 11
1 min read
Related Content
Original Article
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Topics
Hematology/Oncology
Hemostasis and Thrombosis
Clinical Medicine
Ambulatory Medicine